<DOC>
	<DOCNO>NCT01577004</DOCNO>
	<brief_summary>BACKGROUND : Compared epsilon 2 epsilon 3 allele , epsilon 4 allele apolipoprotein E ( ApoE4 ) associate twice prevalence late-onset Alzheimer 's disease ( AD ) . Epidemiological study show risk AD varies inversely consumption omega-3 fatty acid fish seafood . Despite apparently low fish intake AD , pool analysis literature show plasma brain docosahexaenoic acid ( DHA ) actually AD healthy age-matched control . Fish oil trial AD also convince . We recently show ApoE4 carrier 41 % high fasting plasma EPA DHA compare non-carriers , plasma EPA DHA response fish oil ApoE4 carriers half see non-carriers . HYPOTHESES : ( ) Carriers ApoE4 alter metabolism carbon-13 ( 13C ) -DHA well EPA DHA provide dietary supplement . ( ii ) A dietary supplement EPA+DHA improve cognitive performance non-carriers ApoE4 . OBJECTIVES : In carrier non-carriers ApoE4 , compare whether- ) ApoE4 alters incorporation 13C-DHA plasma lipid beta-oxidation . ii ) 13C-DHA metabolism change dietary supplement EPA+DHA ; iii ) Better cognitive performance occur EPA+DHA link raise plasma EPA and/or DHA . EXPERIMENTAL METHODS : Participants older 50 old demented enrol . DHA metabolism evaluate use 13C-DHA EPA+DHA supplement ( 2.4 g/d 5 mo ; n = 20/gp ) . Before last month supplementation , plasma uptake beta-oxidation 50 mg 13C-DHA follow one month . Blood omega-3 fatty acid evaluate monthly supplementation period . Cognitive testing perform 4 month start omega-3 fatty acid supplement . IMPLICATIONS : This project help explain apparent link newly emerge ApoE polymorphism , alter omega-3 fatty acid metabolism risk cognitive decline , help development nutraceutical-based clinical trial use fish oil elderly .</brief_summary>
	<brief_title>Do Apolipoprotein E Polymorphisms Influence Risk Cognitive Decline Modulating Omega-3 Fatty Acid Metabolism ?</brief_title>
	<detailed_description>To come</detailed_description>
	<criteria>MCI define Winblad et al . ( 33 ) , diagnosis confirm geriatrician neuropsychological evaluation do within last 6 month . diagnosis do 6 month ago , subject reevaluate inclusion confirm MCI rather conversion AD . tobacco malnutrition ( assessed blood albumin , haemoglobin lipid ) subject already take EPA+DHA supplement swallow problem , uncontrolled diabetes ( raise fasting glucose , haemoglobin A1c ) uncontrolled thyroid disease severe renal failure chronic immune condition inflammation ( raise Creactive protein , white cell count ) cancer recent major surgery cardiac event uncorrected visual hearing problem dementia ongoing past severe drug alcohol abuse psychiatric difficulty depression evaluate geriatric depression scale test ( 34 ) use psychotropic medication except shortacting benzodiazepine take sleep .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>